OR WAIT 15 SECS
The companies plan to provide characterization testing of container-closure systems for the biopharma industry.
Stevanato Group, an Italian glass primary packaging company, announced on Feb. 5, 2020 that it has entered into an agreement with Pfeiffer Vacuum Technologies to provide characterization testing of container-closure systems for the biopharma industry.
According to a Stevanato press release, the testing services will take place at Stevanato’s new Technology Excellence Center (TEC) in Boston, MA, after it opens during the third quarter of 2020. The new site will offer analytical and testing services for container closure systems and drug delivery devices. It will also provide customized analytics and testing services for biopharma companies’ drug formulation and manufacturing processes.
“The TEC-Pfeiffer Vacuum agreement combines our extensive expertise in glass primary packaging testing with proven CCI [container closure integrity] testing solutions for the biopharma market,” said Abizer Harianawala, TEC site leader, Stevanato, in the press release. “Over the years, biopharma companies have been facing increasingly stricter standard requirements in terms of reliability of CCI testing. Working with Pfeiffer Vacuum Technologies will allow us to support the quality, integrity, and effectiveness of sensitive drugs, preventing issues such as moisture, oxygen, or microbial contamination.”
“Partnering Pfeiffer Vacuum’s industry leadership in CCI technologies with Stevanato Group’s strong experience of the biopharma industry and glass packaging testing is a win-win for both companies as well as packaging suppliers and creates a center of excellence in parenteral drug packaging,” said Brian Pahl, president, Pfeiffer Vacuum Technologies, in the press release.
Stevanato will be showcasing its TEC services at Pharmapack in Paris, France, from Feb. 5–6, 2020.